Comparison Between AT-II-Antagonist And ACE-Inhibitor on Blood Pressure During Exercise in Hypertensives

Ketelhut, Reinhard G.; Franz, I.-W.

doi:10.1249/00005768-200605001-02401

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Candesartan was equally effective as verapamil (a calcium-channel blocker) [Little et al . 2004] and significantly more effective than ramipril (an ACE inhibitor) in blunting the exercise-induced increase in SBP [Ketelhut and Franz, 2006]. The SBP increases were larger after treatment with valsartan than with atenolol (the β-blocker) or the combination of atenolol and valsartan [Czendlik et al .…”

Section: Introductionmentioning

confidence: 99%

Exercise testing in hypertensive patients for assessing the cardiovascular protective potential of antihypertensive drugs

Brunel

Baschiera

Cífková

2013

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Exercise testing is an established noninvasive tool in cardiology used to diagnose and guide treatment in individuals with suspected or confirmed coronary artery disease. Owing to the wealth of information it provides, exercise testing is also being utilized to evaluate prehypertensive stages, characterize hypertension, assess tolerance to exercise and the efficacy of antihypertensive therapies, and predict target organ damage and cardiovascular risk. The literature on exercise tolerance tests is relatively limited since these studies are difficult to conduct although they represent a valuable test for evaluating the benefits of antihypertensive therapies beyond their blood-pressure-lowering efficacy at rest or during exercise. Such a setting can be immensely useful for the evaluation and for the differentiation of treatments, especially in patients with evident rises in systolic blood pressure and with concomitant diseases, who are at higher risk of stroke. Exercise-induced increase in systolic blood pressure from rest to peak exercise should therefore be used as the primary efficacy variable. There is growing evidence that central pressure is a better predictor for cardiovascular risk than peripheral blood pressure, since this variable takes into account the overall effect of vascular aging and increased arterial stiffness that age and other concomitant diseases may induce. It is also important to include central aortic blood pressure and biomarkers of hypertension and cardiac disease in the overall assessment.

show abstract

Section: Introductionmentioning

confidence: 99%